Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections; Omadacycline was Generally Safe and Well-Tolerated
June 16, 2016 16:05 ET
|
Paratek Pharmaceuticals
Company to host a webcast and conference call for investors at 4:30 pm EDT to review top-line results BOSTON, June 16, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK)...
Paratek to Present Omadacycline Microbiologic, Pharmacokinetic and Clinical Data at ASM Microbe 2016
June 13, 2016 16:01 ET
|
Paratek Pharmaceuticals
- Biofilm, post-antibiotic effects, microbiologic surveillance and omadacycline in vitro activity against select pathogens to be presented - Clinical PK and Modelling Strategies for omadacycline to...
Paratek Receives FDA Affirmation for Design of Proposed Omadacycline Oral-Only Skin Infection Phase 3 Study: Opportunity to Accelerate Access to Broader Oral-Only Markets
May 10, 2016 16:01 ET
|
Paratek Pharmaceuticals
FDA Affirms Chosen Comparator, Primary Endpoint for Phase 3 StudyStudy, if Conducted, Would Initiate Following the Reporting of Top-Line Data from IV-to-Oral ABSSSI Phase 3 StudyPotential to...
Paratek Presents Data from Omadacycline Clinical Development Program at ECCMID
April 11, 2016 07:30 ET
|
Paratek Pharmaceuticals
Pooled analysis from Phase 2 and truncated Phase 3 studies demonstrates comparable safety and efficacy profiles for omadacycline compared with linezolid Single dose randomized trial...
Paratek Presents Pre-Clinical Data on the Effects of Omadacycline on Clostridium Difficile
April 11, 2016 07:30 ET
|
Paratek Pharmaceuticals
AMSTERDAM, Netherlands, April 11, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today presented data from two pre-clinical studies evaluating the impact of omadacycline on...
Paratek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 3 Skin Trial
January 06, 2016 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that it projects its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the...